Over 50 representatives from (non-) governmental funders, philanthropies and pharmaceutical companies from around the world…
Piret Baur13 September 2023
Please tell us a bit about yourself. I joined Beacon in October 2022 as Senior…
Ivette Corominas27 February 2023
Please tell us a bit about yourself. I joined EURORDIS in September 2022 as part…
Ivette Corominas22 February 2023
Please tell us a bit about yourself. I’m the CEO of Beacon, formerly an evolutionary…
Ivette Corominas15 February 2023
, Horizon Magazine published an article on drug repurposing featuring REMEDi4ALL project. According to the…
Ivette Corominas30 November 2022
Virginie Hivert, Director of Therapeutic Development at Eurordis, was recently interviewed by Phamaceutiques
Ivette Corominas30 November 2022
Every year, approximately 140.000 people are diagnosed with pancreatic cancer in Europe. This is one…
Ivette Corominas17 November 2022
The iconic building The Eye in central Amsterdam, welcomed the REMEDi4ALL Consortium last September for…
Gisela Pairo4 November 2022
Researchers from Oswaldo Cruz Foundation - Fiocruz - in Brazil, have published a paper on…
Piret Baur28 October 2022
REMEDi4ALL has just launched a call inviting research funders to share their experience and ideas…
Gisela Pairo28 October 2022
REMEDi4ALL, an ambitious EU-funded research initiative, launches today to drive forward the repurposing of medicines…
admin1 September 2022
The repurposing of existing medicines has the potential to greatly improve public health outcomes, especially on neglected and rare…
admin24 August 2022
Since the beginning of the pandemic, researchers worldwide have been looking for ways to treat…
admin18 August 2022
A recent study conducted in an Egyptian hospital showed that treating moderate-to-severe COVID patients with…
admin12 August 2022
A new study presents a novel approach to drug repurposing that incorporates two-stage prediction and…
admin10 August 2022
Sign up to receive the latest project-related news and opportunities
You can unsubscribe at any time.
